tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

HUMA Stock Latest News

Humacyte price target lowered to $6 from $7 at BTIG
The FlyHumacyte price target lowered to $6 from $7 at BTIG
7d ago
HUMA
Humacyte Announces $60M Stock and Warrants Offering
PremiumCompany Announcements
Humacyte Announces $60M Stock and Warrants Offering
13d ago
8K
HUMA
Humacyte prices 28.4M shares at $2.11 in registered direct offering
PremiumThe Fly
Humacyte prices 28.4M shares at $2.11 in registered direct offering
13d ago
HUMA
Promising Potential of Humacyte’s Symvess: Buy Rating Backed by Strong Efficacy and Market Position
PremiumRatings
Promising Potential of Humacyte’s Symvess: Buy Rating Backed by Strong Efficacy and Market Position
14d ago
HUMA
Humacyte announces publication of Symvess results in real-world combat
PremiumThe Fly
Humacyte announces publication of Symvess results in real-world combat
14d ago
HUMA
Humacyte announces allowance of U.S. patent for bioengineered esophagus
PremiumThe FlyHumacyte announces allowance of U.S. patent for bioengineered esophagus
21d ago
HUMA
Humacyte announces preclinical data on CTEV use
Premium
The Fly
Humacyte announces preclinical data on CTEV use
1M ago
HUMA
Humacyte Amends Revenue Agreement with TPC Investments
Premium
Company Announcements
Humacyte Amends Revenue Agreement with TPC Investments
1M ago
8K
HUMA
Humacyte announces publication of outcomes for patients treated with Symvess
PremiumThe Fly
Humacyte announces publication of outcomes for patients treated with Symvess
1M ago
HUMA
Humacyte files $350M mixed securities shelf
PremiumThe Fly
Humacyte files $350M mixed securities shelf
1M ago
HUMA
Humacyte initiated with an Overweight at Barclays
PremiumThe Fly
Humacyte initiated with an Overweight at Barclays
2M ago
HUMA
Humacyte’s Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Humacyte’s Earnings Call: Progress Amid Challenges
2M ago
HUMA
Humacyte price target lowered to $3.50 from $5 at TD Cowen
PremiumThe FlyHumacyte price target lowered to $3.50 from $5 at TD Cowen
2M ago
HUMA
Humacyte’s Strategic Positioning and Growth Potential Justifies Buy Rating Despite Revenue Shortfall
Premium
Ratings
Humacyte’s Strategic Positioning and Growth Potential Justifies Buy Rating Despite Revenue Shortfall
2M ago
HUMA
Humacyte price target lowered to $3 from $4 at H.C. Wainwright
Premium
The Fly
Humacyte price target lowered to $3 from $4 at H.C. Wainwright
2M ago
HUMA
Humacyte Reports Q2 2025 Earnings and Market Expansion
PremiumCompany Announcements
Humacyte Reports Q2 2025 Earnings and Market Expansion
2M ago
HUMA
Buy Rating Reaffirmed for Humacyte Amid Promising Symvess Launch and Strategic Collaborations
PremiumRatings
Buy Rating Reaffirmed for Humacyte Amid Promising Symvess Launch and Strategic Collaborations
2M ago
HUMA
Humacyte reports Q2 EPS (24c), consensus (18c)
PremiumThe Fly
Humacyte reports Q2 EPS (24c), consensus (18c)
2M ago
HUMA
Is HUMA a Buy, Before Earnings?
PremiumPre-Earnings
Is HUMA a Buy, Before Earnings?
2M ago
HUMA
Humacyte’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Josh Jennings
PremiumRatingsHumacyte’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Josh Jennings
3M ago
HUMA
Humacyte announces first sale of Symvess to U.S. Military Treatment Facility
Premium
The Fly
Humacyte announces first sale of Symvess to U.S. Military Treatment Facility
3M ago
HUMA
Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
Premium
The Fly
Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
3M ago
BA
EXK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >